The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study
Andrew D Barreto, Andrei V Alexandrov, Pat Lyden, Jessica Lee, Sheryl Martin-Schild, Loren Shen, Tzu-Ching Wu, April Sisson, Renganayaki Pandurengan, Zhongxue Chen, Mohammad H Rahbar, Clotilde Balucani, Kristian Barlinn, Rebecca M Sugg, Zsolt Garami, Georgios Tsivgoulis, Nicole R Gonzales, Sean I Savitz, Robert Mikulik, Andrew M Demchuk, James C Grotta, Andrew D Barreto, Andrei V Alexandrov, Pat Lyden, Jessica Lee, Sheryl Martin-Schild, Loren Shen, Tzu-Ching Wu, April Sisson, Renganayaki Pandurengan, Zhongxue Chen, Mohammad H Rahbar, Clotilde Balucani, Kristian Barlinn, Rebecca M Sugg, Zsolt Garami, Georgios Tsivgoulis, Nicole R Gonzales, Sean I Savitz, Robert Mikulik, Andrew M Demchuk, James C Grotta
Abstract
Background and purpose: Argatroban is a direct thrombin inhibitor that safely augments recanalization achieved by tissue-type plasminogen activator (tPA) in animal stroke models. The Argatroban tPA Stroke Study was an open-label, pilot safety study of tPA plus Argatroban in patients with ischemic stroke due to proximal intracranial occlusion.
Methods: During standard-dose intravenous tPA, a 100-μg/kg bolus of Argatroban and infusion for 48 hours was adjusted to a target partial thromboplastin time of 1.75× baseline. The primary outcome was incidence of significant intracerebral hemorrhage defined as either symptomatic intracerebral hemorrhage or Parenchymal Hematoma Type 2. Recanalization was measured at 2 and 24 hours by transcranial Doppler or CT angiography.
Results: Sixty-five patients were enrolled (45% men, mean age 63±14 years, median National Institutes of Health Stroke Scale=13). The median (interquartile range) time tPA to Argatroban bolus was 51 (38-60) minutes. Target anticoagulation was reached at a median (interquartile range) of 3 (2-7) hours. Significant intracerebral hemorrhage occurred in 4 patients (6.2%; 95% CI, 1.7-15.0). Of these, 3 were symptomatic (4.6%; 95% CI, 0.9-12.9). Seven patients (10%) died in the first 7 days. Within the 2-hour monitoring period, transcranial Doppler recanalization (n=47) occurred in 29 (61%) patients: complete in 19 (40%) and partial in another 10 (21%).
Conclusions: The combination of Argatroban and intravenous tPA is potentially safe in patients with moderate neurological deficits due to proximal intracranial arterial occlusions and may produce more complete recanalization than tPA alone. Continued evaluation of this treatment combination is warranted.
Clinical trial registration: URL: www.clinicaltrials.gov. Unique identifier: NCT00268762.
Conflict of interest statement
Conflict of Interest
Figures
Source: PubMed